BCL2 and cancer: Some target genes of miR-204 have been validated in cancer cells, such as BCL2 in cholangiocarcinoma, colon cancer and neuroblastoma, BNDF and JAK 2 in breast cancer, Cyclin D2 in retinoblastoma, EPHB2 in glioma, IGFPB5 in papillary thyroid carcinoma [220], and SHP2 in cutaneous squamous cell carcinoma [48].